Theravance Reports First Patient Dosing in P-I Study with TD-0903 to Treat Patients with Acute Lung Injury Associated with COVID-19

Shots: :Stosohth:ththShots:

• The company reported the dosing of a first healthy volunteer in a P-I study of TD-0903 and anticipates that TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to ARDS
• Earlier, Theravance has received approval to initiate the P-I study for assessing safety, tolerability and pharmacokinetics of SAD/MAD of TD-0903 in healthy volunteers and will enroll up to 54 volunteers in the UK. Following the regulatory review and approval, the program will move to P-II study in the same clinical setting
• TD-0903 is a lung-selective, nebulized pan-JAK inhibitor and showed the reduction in the signaling of multiple cytokines associated with cytokine storm syndrome in its preclinical study

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: PRNewswire